Cargando…
SARS-CoV-2 antibody testing—questions to be asked
Severe acute respiratory syndrome coronavirus 2 infection and development of coronavirus disease 2019 presents a major health care challenge of global dimensions. Laboratory diagnostics of infected patients, and the assessment of immunity against severe acute respiratory syndrome coronavirus 2, pres...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256507/ https://www.ncbi.nlm.nih.gov/pubmed/32479758 http://dx.doi.org/10.1016/j.jaci.2020.05.020 |
_version_ | 1783539924471906304 |
---|---|
author | Özçürümez, Mustafa K. Ambrosch, Andreas Frey, Oliver Haselmann, Verena Holdenrieder, Stefan Kiehntopf, Michael Neumaier, Michael Walter, Michael Wenzel, Folker Wölfel, Roman Renz, Harald |
author_facet | Özçürümez, Mustafa K. Ambrosch, Andreas Frey, Oliver Haselmann, Verena Holdenrieder, Stefan Kiehntopf, Michael Neumaier, Michael Walter, Michael Wenzel, Folker Wölfel, Roman Renz, Harald |
author_sort | Özçürümez, Mustafa K. |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 infection and development of coronavirus disease 2019 presents a major health care challenge of global dimensions. Laboratory diagnostics of infected patients, and the assessment of immunity against severe acute respiratory syndrome coronavirus 2, presents a major cornerstone in handling the pandemic. Currently, there is an increase in demand for antibody testing and a large number of tests are already marketed or are in the late stage of development. However, the interpretation of test results depends on many variables and factors, including sensitivity, specificity, potential cross-reactivity and cross-protectivity, the diagnostic value of antibodies of different isotypes, and the use of antibody testing in identification of acutely ill patients or in epidemiological settings. In this article, the recently established COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) addresses these issues on the basis of currently available data sets in this rapidly moving field. |
format | Online Article Text |
id | pubmed-7256507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Academy of Allergy, Asthma & Immunology |
record_format | MEDLINE/PubMed |
spelling | pubmed-72565072020-05-29 SARS-CoV-2 antibody testing—questions to be asked Özçürümez, Mustafa K. Ambrosch, Andreas Frey, Oliver Haselmann, Verena Holdenrieder, Stefan Kiehntopf, Michael Neumaier, Michael Walter, Michael Wenzel, Folker Wölfel, Roman Renz, Harald J Allergy Clin Immunol Reviews and Feature Articles Severe acute respiratory syndrome coronavirus 2 infection and development of coronavirus disease 2019 presents a major health care challenge of global dimensions. Laboratory diagnostics of infected patients, and the assessment of immunity against severe acute respiratory syndrome coronavirus 2, presents a major cornerstone in handling the pandemic. Currently, there is an increase in demand for antibody testing and a large number of tests are already marketed or are in the late stage of development. However, the interpretation of test results depends on many variables and factors, including sensitivity, specificity, potential cross-reactivity and cross-protectivity, the diagnostic value of antibodies of different isotypes, and the use of antibody testing in identification of acutely ill patients or in epidemiological settings. In this article, the recently established COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) addresses these issues on the basis of currently available data sets in this rapidly moving field. American Academy of Allergy, Asthma & Immunology 2020-07 2020-05-29 /pmc/articles/PMC7256507/ /pubmed/32479758 http://dx.doi.org/10.1016/j.jaci.2020.05.020 Text en © 2020 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Reviews and Feature Articles Özçürümez, Mustafa K. Ambrosch, Andreas Frey, Oliver Haselmann, Verena Holdenrieder, Stefan Kiehntopf, Michael Neumaier, Michael Walter, Michael Wenzel, Folker Wölfel, Roman Renz, Harald SARS-CoV-2 antibody testing—questions to be asked |
title | SARS-CoV-2 antibody testing—questions to be asked |
title_full | SARS-CoV-2 antibody testing—questions to be asked |
title_fullStr | SARS-CoV-2 antibody testing—questions to be asked |
title_full_unstemmed | SARS-CoV-2 antibody testing—questions to be asked |
title_short | SARS-CoV-2 antibody testing—questions to be asked |
title_sort | sars-cov-2 antibody testing—questions to be asked |
topic | Reviews and Feature Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256507/ https://www.ncbi.nlm.nih.gov/pubmed/32479758 http://dx.doi.org/10.1016/j.jaci.2020.05.020 |
work_keys_str_mv | AT ozcurumezmustafak sarscov2antibodytestingquestionstobeasked AT ambroschandreas sarscov2antibodytestingquestionstobeasked AT freyoliver sarscov2antibodytestingquestionstobeasked AT haselmannverena sarscov2antibodytestingquestionstobeasked AT holdenriederstefan sarscov2antibodytestingquestionstobeasked AT kiehntopfmichael sarscov2antibodytestingquestionstobeasked AT neumaiermichael sarscov2antibodytestingquestionstobeasked AT waltermichael sarscov2antibodytestingquestionstobeasked AT wenzelfolker sarscov2antibodytestingquestionstobeasked AT wolfelroman sarscov2antibodytestingquestionstobeasked AT renzharald sarscov2antibodytestingquestionstobeasked AT sarscov2antibodytestingquestionstobeasked |